Garcia-Casado et al. BMC Cancer 2010, 10:36 http://www.biomedcentral.com/1471-2407/10/36 9. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348(24):2431-2442. 10. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20(3):751-757. 11. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110(2):244-254. 12. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001, 12(11):1527-1532. 13. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB- 2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19(18):3808-3816. 14. Smith I, Dowsett M, trialists oboI: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in posmenopausal women: The IMPACT trial. Breast Cancer Res Treat 2003, 82(suppl 2):S9-S15. 15. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, et al: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96(12):936-945. 16. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, et al: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13(1):94-101. 17. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, et al: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67(5):1893-1897. 18. Ribeiro FS, de Amorim LM, de Almeida Simao T, Mendonca GA, de Moura Gallo CV, Pinto LF: CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women. Toxicol Lett 2006, 164(1):90-95. 19. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen- Dale AL: A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8(1):43-48. 20. Baxter SW, Choong DY, Eccles DM, Campbell IG: Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001, 22(2):347-349. 21. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE: Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999, 6(2):165-173. 22. Thyagarajan B, Brott M, Mink P, Folsom AR, Anderson KE, Oetting WS, Gross M: CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 2004, 207(2):183-189. 23. Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD, Jupe ER: Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 2007, 109(10):1940-1948. 24. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, et al: A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2007, 102(2):237-247. 25. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL: Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 19(10):1329-1333. 26. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ: No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(2):215-216. 27. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, et al: Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and Page 11 of 11 prognosis in breast cancer patients. Breast Cancer Res Treat 2008, 112(1):89-98. 28. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, Zheng W: Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2115-2122. 29. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Munoz M, et al: A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14(3):811-816. 30. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. . Histopathology 2002, 41(3A):151, Comment on C. W. Elston 19; 403-410. 31. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, et al: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001, 19(6):1698-1706. 32. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, et al: Human aromatase: gene resequencing and functional genomics. Cancer Res 2005, 65(23):11071-11082. 33. Stern C: The Hardy-Weinberg Law. Science 1943, 97(2510):137-138. 34. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481. 35. Peto R, Peto P: Asymptomatically efficient rank invariant test procedures. J Roy Stat Soc 1987, 135:185-206. 36. Cox D: Regression models and life tables. J R Stat Soc 1972, 34:187-220. 37. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47(1):207-214. 38. Dowsett M, Martin LA, Smith I, Johnston S: Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005, 95(1-5):167-172. 39. Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008, 100(9):642-648. 40. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S: Organization of the human aromatase p450 (CYP19) gene. Seminars in reproductive medicine 2004, 22(1):5-9. 41. Rhiem K, Klein A, Munch M, Kreutzfeld R, Ramser J, Wardelmann E, Schackert G, Von Deimling A, Wiestler OD, Schmutzler RK: Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003, 106(1):74-77. 42. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer–a study from the IMPACT trialists. J Clin Oncol 2005, 23(11):2477-2492. 43. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, et al: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9(3):R37. Pre-publication history The pre-publication history for this paper can be accessed here:http://www. biomedcentral.com/1471-2407/10/36/prepub doi:10.1186/1471-2407-10-36 Cite this article as: Garcia-Casado et al.: A polymorphism at the 3’-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010 10:36.